138 related articles for article (PubMed ID: 10963181)
1. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning.
Watanabe H; Shinozaki T; Yanagawa T; Aoki J; Tokunaga M; Inoue T; Endo K; Mohara S; Sano K; Takagishi K
J Bone Joint Surg Br; 2000 Jul; 82(5):760-7. PubMed ID: 10963181
[TBL] [Abstract][Full Text] [Related]
2. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.
Watanabe H; Inoue T; Shinozaki T; Yanagawa T; Ahmed AR; Tomiyoshi K; Oriuchi N; Tokunaga M; Aoki J; Endo K; Takagishi K
Eur J Nucl Med; 2000 Oct; 27(10):1509-17. PubMed ID: 11083540
[TBL] [Abstract][Full Text] [Related]
4. Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography.
Yanagawa T; Watanabe H; Inoue T; Ahmed AR; Tomiyoshi K; Shinozaki T; Oriuchi N; Endo K; Takagishi K
J Comput Assist Tomogr; 2003; 27(2):175-82. PubMed ID: 12703009
[TBL] [Abstract][Full Text] [Related]
5. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.
Zhang H; Tian M; Oriuchi N; Higuchi T; Watanabe H; Aoki J; Tanada S; Endo K
Nucl Med Commun; 2003 Mar; 24(3):273-9. PubMed ID: 12612468
[TBL] [Abstract][Full Text] [Related]
6. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
[TBL] [Abstract][Full Text] [Related]
7. 18FDG PET scanning of benign and malignant musculoskeletal lesions.
Feldman F; van Heertum R; Manos C
Skeletal Radiol; 2003 Apr; 32(4):201-8. PubMed ID: 12652335
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas.
Schwarzbach MH; Hinz U; Dimitrakopoulou-Strauss A; Willeke F; Cardona S; Mechtersheimer G; Lehnert T; Strauss LG; Herfarth C; Büchler MW
Ann Surg; 2005 Feb; 241(2):286-94. PubMed ID: 15650639
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.
Aoki J; Watanabe H; Shinozaki T; Takagishi K; Tokunaga M; Koyama Y; Sato N; Endo K
Skeletal Radiol; 2003 Mar; 32(3):133-8. PubMed ID: 12605276
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.
Tian M; Zhang H; Oriuchi N; Higuchi T; Endo K
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1064-72. PubMed ID: 15014903
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET for evaluating musculoskeletal tumors: a review.
Aoki J; Endo K; Watanabe H; Shinozaki T; Yanagawa T; Ahmed AR; Takagishi K
J Orthop Sci; 2003; 8(3):435-41. PubMed ID: 12768492
[TBL] [Abstract][Full Text] [Related]
12. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
[TBL] [Abstract][Full Text] [Related]
14. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible?
Schulte M; Brecht-Krauss D; Heymer B; Guhlmann A; Hartwig E; Sarkar MR; Diederichs CG; Schultheiss M; Kotzerke J; Reske SN
Eur J Nucl Med; 1999 Jun; 26(6):599-605. PubMed ID: 10369945
[TBL] [Abstract][Full Text] [Related]
17. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography.
Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Hasegawa T
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):683-91. PubMed ID: 16506050
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors.
Miwa S; Mochizuki T; Yamamoto N; Shirai T; Hayashi K; Takeuchi A; Inatani H; Igarashi K; Higuchi T; Abe K; Taniguchi Y; Aiba H; Ikeda H; Tsuchiya H
Anticancer Res; 2018 Jul; 38(7):4065-4072. PubMed ID: 29970532
[TBL] [Abstract][Full Text] [Related]
19. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
20. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?
Walter F; Czernin J; Hall T; Allen-Auerbach M; Walter MA; Dunkelmann S; Federman N
J Pediatr Hematol Oncol; 2012 Mar; 34(2):131-6. PubMed ID: 22134608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
